Food and Drug Administration (FDA) Research Food and Drug Administration (FDA) RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Patient reported outcome measures (PRO) in colorectal surgery
Surg Open Sci. 2024 Mar 28;19:66-69. doi: 10.1016/j.sopen.2024.03.013. eCollection 2024 Jun.ABSTRACTPatient reported outcomes refer to, "Any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (US Food and Drug Administration, 2009) [1]. These outcomes can include anything that matters to patients including quality of life, pain, number of bowel movements. Patient reported outcome measures refer to tools or instruments that help to measure these outcomes. These measures can be done using validated tools, t...
Source: Pain Physician - April 10, 2024 Category: Anesthesiology Authors: Kathia E Nitsch Srinivas J Ivatury Source Type: research

Patient reported outcome measures (PRO) in colorectal surgery
Surg Open Sci. 2024 Mar 28;19:66-69. doi: 10.1016/j.sopen.2024.03.013. eCollection 2024 Jun.ABSTRACTPatient reported outcomes refer to, "Any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (US Food and Drug Administration, 2009) [1]. These outcomes can include anything that matters to patients including quality of life, pain, number of bowel movements. Patient reported outcome measures refer to tools or instruments that help to measure these outcomes. These measures can be done using validated tools, t...
Source: Pain Physician - April 10, 2024 Category: Anesthesiology Authors: Kathia E Nitsch Srinivas J Ivatury Source Type: research

GSE263394 Dolutegravir induces FOLR1 expression during brain organoid development.
Contributors : Daniel Kraushaar ; Carlo Donato Caiaffa ; Robert M CabreraSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe brain and spinal cord are formed during neurulation, a developmental process that occurs during the first month of pregnancy and can be modified by low serum levels of folic acid (FA), environmental factors, or genetic predispositions. In 2018, data from a surveillance study in Botswana, a country with one of the highest incidences of human immunodeficiency virus (HIV) and lacking mandatory food folate fortification programs, revealed an increased risk of neur...
Source: GEO: Gene Expression Omnibus - April 10, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Dose optimization for cancer treatments with considerations for late-onset toxicities
Clin Trials. 2024 Apr 9:17407745231221152. doi: 10.1177/17407745231221152. Online ahead of print.ABSTRACTGiven that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort to move away from considering the maximum tolerated dose as the optimal dose, the Food and Drug Administration Project Optimus points to the need of incorporating long-term toxicity evaluation, given that many of these novel agents lead to late-onset or cumulative toxicities and there are no guidelines on how to handle them. Numerous method...
Source: Clinical Trials - April 9, 2024 Category: Research Authors: Lucie Biard Ana ïs Andrillon Rebecca B Silva Shing M Lee Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Dose optimization for cancer treatments with considerations for late-onset toxicities
Clin Trials. 2024 Apr 9:17407745231221152. doi: 10.1177/17407745231221152. Online ahead of print.ABSTRACTGiven that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort to move away from considering the maximum tolerated dose as the optimal dose, the Food and Drug Administration Project Optimus points to the need of incorporating long-term toxicity evaluation, given that many of these novel agents lead to late-onset or cumulative toxicities and there are no guidelines on how to handle them. Numerous method...
Source: Clinical Trials - April 9, 2024 Category: Research Authors: Lucie Biard Ana ïs Andrillon Rebecca B Silva Shing M Lee Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Dose optimization for cancer treatments with considerations for late-onset toxicities
Clin Trials. 2024 Apr 9:17407745231221152. doi: 10.1177/17407745231221152. Online ahead of print.ABSTRACTGiven that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort to move away from considering the maximum tolerated dose as the optimal dose, the Food and Drug Administration Project Optimus points to the need of incorporating long-term toxicity evaluation, given that many of these novel agents lead to late-onset or cumulative toxicities and there are no guidelines on how to handle them. Numerous method...
Source: Clinical Trials - April 9, 2024 Category: Research Authors: Lucie Biard Ana ïs Andrillon Rebecca B Silva Shing M Lee Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Dose optimization for cancer treatments with considerations for late-onset toxicities
Clin Trials. 2024 Apr 9:17407745231221152. doi: 10.1177/17407745231221152. Online ahead of print.ABSTRACTGiven that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort to move away from considering the maximum tolerated dose as the optimal dose, the Food and Drug Administration Project Optimus points to the need of incorporating long-term toxicity evaluation, given that many of these novel agents lead to late-onset or cumulative toxicities and there are no guidelines on how to handle them. Numerous method...
Source: Clinical Trials - April 9, 2024 Category: Research Authors: Lucie Biard Ana ïs Andrillon Rebecca B Silva Shing M Lee Source Type: research

Dose optimization for cancer treatments with considerations for late-onset toxicities
Clin Trials. 2024 Apr 9:17407745231221152. doi: 10.1177/17407745231221152. Online ahead of print.ABSTRACTGiven that novel anticancer therapies have different toxicity profiles and mechanisms of action, it is important to reconsider the current approaches for dose selection. In an effort to move away from considering the maximum tolerated dose as the optimal dose, the Food and Drug Administration Project Optimus points to the need of incorporating long-term toxicity evaluation, given that many of these novel agents lead to late-onset or cumulative toxicities and there are no guidelines on how to handle them. Numerous method...
Source: Clinical Trials - April 9, 2024 Category: Research Authors: Lucie Biard Ana ïs Andrillon Rebecca B Silva Shing M Lee Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research

Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions
The use of T-cell re-directing therapy in multiple myeloma (MM) is promising. [1] Two chimeric antigen T cell receptor therapy (CAR-T) products: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) and three bispecific antibodies (BsAbs): (Teclistamab-cqyv, Talquetamab-tgvs, and Elranatamab-bcmm) are currently approved by the Food and Drug Administration (FDA) to use in relapsed/refractory (R/R) MM after receiving four or more prior lines of therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Samer Al Hadidi Tags: Editorial Source Type: research